Therapeutic Group

Indication Dosage

Trastuzumab emtansine, commonly known as T-DM1, is a medication indicated for the treatment of HER2-positive breast cancer. It is prescribed for patients who have previously received trastuzumab (Herceptin) and a taxane chemotherapy, either separately or in combination, and whose cancer has progressed despite these treatments. T-DM1 works by targeting HER2 receptors on cancer cells, delivering a potent chemotherapy drug directly to the tumor, thereby inhibiting cancer cell growth and reducing the spread of the disease.

Monotherapy For The Treatment Of Her2-positive, Unresectable, Locally Advanced Or Metastatic Breast Cancer, In Adult Patients Who Have Previously Received Trastuzumab Separately Or In Combination, Or Who Have Developed Disease Recurrence During Or Within 6 Months Of Completing Adjuvant Therapy: 

By IV Infusion: 

• Adults: 4mg/kg Iv Over 90 Mins. Maintenance: 2mg/kg IV over 30 Min Every Week.

Content

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

Contra Indications

Precautions

Lactation

Side Effects